tiprankstipranks
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

2,165 Followers
See the Price Targets and Ratings of:

ACAD Analyst Ratings

Moderate Buy
18Ratings
13 Buy
5 Hold
0 Sell
Based on 18 analysts giving stock ratings to
ACADIA
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACAD Stock 12 Month Forecast

Average Price Target

$27.94
▲(83.82% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $27.94 with a high forecast of $39.00 and a low forecast of $17.00. The average price target represents a 83.82% change from the last price of $15.20.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","22":"$22","28":"$28","34":"$34","40":"$40"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$27.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,22,28,34,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.05,18.73846153846154,20.426923076923078,22.115384615384617,23.803846153846155,25.49230769230769,27.18076923076923,28.869230769230768,30.557692307692307,32.246153846153845,33.934615384615384,35.62307692307692,37.31153846153846,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.05,17.88769230769231,18.725384615384616,19.563076923076924,20.40076923076923,21.23846153846154,22.076153846153847,22.913846153846155,23.751538461538463,24.58923076923077,25.426923076923078,26.264615384615386,27.102307692307694,{"y":27.94,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.05,17.046153846153846,17.04230769230769,17.03846153846154,17.034615384615385,17.03076923076923,17.026923076923076,17.023076923076925,17.01923076923077,17.015384615384615,17.01153846153846,17.00769230769231,17.003846153846155,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.78,"date":1685059200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.19,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.79,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.68,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.07,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.33,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.29,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.01,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.01,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.05,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$39.00Average Price Target$27.94Lowest Price Target$17.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities
$21.00
Hold
38.16%
Upside
Reiterated
05/08/24
Acadia Pharmaceuticals price target lowered to $21 from $25 at MizuhoAcadia Pharmaceuticals price target lowered to $21 from $25 at Mizuho
Citi
$30.00
Buy
97.37%
Upside
Reiterated
05/08/24
Acadia Pharmaceuticals price target lowered to $30 from $30.19 at CitiAcadia Pharmaceuticals price target lowered to $30 from $30.19 at Citi
UBS
$27.00
Buy
77.63%
Upside
Reiterated
04/30/24
Acadia Pharmaceuticals (ACAD) PT Lowered to $27 at UBSUBS analyst Ashwani Verma lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $27.00 (from $33.00) while maintaining a Buy rating.
J.P. Morgan
$25.00
Buy
64.47%
Upside
Reiterated
03/25/24
Acadia Pharmaceuticals price target lowered to $25 from $29 at JPMorganAcadia Pharmaceuticals price target lowered to $25 from $29 at JPMorgan
Morgan Stanley
$30.00
Buy
97.37%
Upside
Reiterated
03/13/24
Acadia Pharmaceuticals price target lowered to $30 from $40 at Morgan StanleyAcadia Pharmaceuticals price target lowered to $30 from $40 at Morgan Stanley

Best Analysts Covering ACADIA Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy ACAD and Sell After:
1 Month
Marc GoodmanLeerink Partners
Success Rate
13/26 ratings generated profit
50%
Average Return
-3.46%
reiterated a buy rating 20 days ago
Copying Marc Goodman's trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -3.46% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Ritu BaralTD Cowen
Success Rate
15/23 ratings generated profit
65%
Average Return
+7.27%
reiterated a buy rating 3 months ago
Copying Ritu Baral's trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +7.27% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Ritu BaralTD Cowen
Success Rate
14/23 ratings generated profit
61%
Average Return
+8.46%
reiterated a buy rating 3 months ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 60.87% of your transactions generating a profit, with an average return of +8.46% per trade.
2 Years
Charles DuncanCantor Fitzgerald
Success Rate
11/33 ratings generated profit
33%
Average Return
+7.34%
reiterated a buy rating 3 months ago
Copying Charles Duncan's trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +7.34% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACAD Analyst Recommendation Trends

Rating
Jan 24
Feb 24
Mar 24
Apr 24
May 24
Strong Buy
6
12
19
22
19
Buy
17
19
17
11
6
Hold
8
9
8
8
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
40
44
41
34
In the current month, ACAD has received 25 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. ACAD average Analyst price target in the past 3 months is $27.94.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

ACAD Financial Forecast

ACAD Earnings Forecast

Next quarter’s earnings estimate for ACAD is $0.19 with a range of $0.09 to $0.34. The previous quarter’s EPS was $0.10. ACAD beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.39% of the time in the same period. In the last calendar year ACAD has Outperformed its overall industry.
Next quarter’s earnings estimate for ACAD is $0.19 with a range of $0.09 to $0.34. The previous quarter’s EPS was $0.10. ACAD beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.39% of the time in the same period. In the last calendar year ACAD has Outperformed its overall industry.

ACAD Sales Forecast

Next quarter’s sales forecast for ACAD is $236.11M with a range of $225.00M to $245.60M. The previous quarter’s sales results were $205.83M. ACAD beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.25% of the time in the same period. In the last calendar year ACAD has Outperformed its overall industry.
Next quarter’s sales forecast for ACAD is $236.11M with a range of $225.00M to $245.60M. The previous quarter’s sales results were $205.83M. ACAD beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.25% of the time in the same period. In the last calendar year ACAD has Outperformed its overall industry.

ACAD Stock Forecast FAQ

What is ACAD’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is $27.94.
    What is ACAD’s upside potential, based on the analysts’ average price target?
    ACADIA Pharmaceuticals has 83.82% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACAD a Buy, Sell or Hold?
          ACADIA Pharmaceuticals has a consensus rating of Moderate Buy which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.
            What is ACADIA Pharmaceuticals’s price target?
            The average price target for ACADIA Pharmaceuticals is $27.94. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $39.00 ,the lowest forecast is $17.00. The average price target represents 83.82% Increase from the current price of $15.2.
              What do analysts say about ACADIA Pharmaceuticals?
              ACADIA Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of ACAD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis